OTCMKTS:PKPH

Peak Pharmaceuticals Competitors

$0.13
0.00 (-1.44 %)
(As of 04/16/2021 08:10 PM ET)
Add
Compare
Today's Range
$0.12
Now: $0.13
$0.13
50-Day Range
$0.13
MA: $0.15
$0.20
52-Week Range
$0.01
Now: $0.13
$0.27
Volume174,400 shs
Average Volume427,649 shs
Market Capitalization$10.19 million
P/E RatioN/A
Dividend YieldN/A
Beta0.46

Competitors

Peak Pharmaceuticals (OTCMKTS:PKPH) Vs. IIPR, GRWG, XXII, KSHB, NSAV, and TRTC

Should you be buying PKPH stock or one of its competitors? Companies in the sub-industry of "cannabis" are considered alternatives and competitors to Peak Pharmaceuticals, including Innovative Industrial Properties (IIPR), GrowGeneration (GRWG), 22nd Century Group (XXII), KushCo (KSHB), NSAV (NSAV), and Terra Tech (TRTC).

Peak Pharmaceuticals (OTCMKTS:PKPH) and Innovative Industrial Properties (NYSE:IIPR) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, analyst recommendations and risk.

Insider and Institutional Ownership

74.9% of Innovative Industrial Properties shares are owned by institutional investors. 2.9% of Innovative Industrial Properties shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Peak Pharmaceuticals and Innovative Industrial Properties' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Peak PharmaceuticalsN/AN/AN/AN/AN/A
Innovative Industrial Properties$44.67 million97.38$23.48 million$3.2755.60

Innovative Industrial Properties has higher revenue and earnings than Peak Pharmaceuticals.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Peak Pharmaceuticals and Innovative Industrial Properties, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Peak Pharmaceuticals0000N/A
Innovative Industrial Properties02502.71

Innovative Industrial Properties has a consensus target price of $192.4286, indicating a potential upside of 6.03%. Given Innovative Industrial Properties' higher possible upside, analysts clearly believe Innovative Industrial Properties is more favorable than Peak Pharmaceuticals.

Risk & Volatility

Peak Pharmaceuticals has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Comparatively, Innovative Industrial Properties has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500.

Profitability

This table compares Peak Pharmaceuticals and Innovative Industrial Properties' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Peak PharmaceuticalsN/AN/AN/A
Innovative Industrial Properties55.71%6.05%4.82%

Summary

Innovative Industrial Properties beats Peak Pharmaceuticals on 9 of the 9 factors compared between the two stocks.

Peak Pharmaceuticals (OTCMKTS:PKPH) and GrowGeneration (NASDAQ:GRWG) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Peak Pharmaceuticals and GrowGeneration's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Peak PharmaceuticalsN/AN/AN/A
GrowGeneration2.14%4.68%3.53%

Insider & Institutional Ownership

51.3% of GrowGeneration shares are held by institutional investors. 13.6% of GrowGeneration shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Peak Pharmaceuticals has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Comparatively, GrowGeneration has a beta of 3.09, meaning that its share price is 209% more volatile than the S&P 500.

Valuation & Earnings

This table compares Peak Pharmaceuticals and GrowGeneration's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Peak PharmaceuticalsN/AN/AN/AN/AN/A
GrowGeneration$79 million33.42$1.88 million$0.10451.60

GrowGeneration has higher revenue and earnings than Peak Pharmaceuticals.

Analyst Recommendations

This is a summary of recent ratings and price targets for Peak Pharmaceuticals and GrowGeneration, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Peak Pharmaceuticals0000N/A
GrowGeneration03502.63

GrowGeneration has a consensus price target of $49.5714, indicating a potential upside of 9.94%. Given GrowGeneration's higher possible upside, analysts clearly believe GrowGeneration is more favorable than Peak Pharmaceuticals.

Summary

GrowGeneration beats Peak Pharmaceuticals on 9 of the 9 factors compared between the two stocks.

Peak Pharmaceuticals (OTCMKTS:PKPH) and 22nd Century Group (NYSEAMERICAN:XXII) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership.

Valuation and Earnings

This table compares Peak Pharmaceuticals and 22nd Century Group's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Peak PharmaceuticalsN/AN/AN/AN/AN/A
22nd Century GroupN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and recommmendations for Peak Pharmaceuticals and 22nd Century Group, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Peak Pharmaceuticals0000N/A
22nd Century Group00103.00

Profitability

This table compares Peak Pharmaceuticals and 22nd Century Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Peak PharmaceuticalsN/AN/AN/A
22nd Century GroupN/AN/AN/A

Summary

22nd Century Group beats Peak Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

KushCo (OTCMKTS:KSHB) and Peak Pharmaceuticals (OTCMKTS:PKPH) are both small-cap multi-sector conglomerates companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Insider and Institutional Ownership

0.0% of KushCo shares are owned by institutional investors. 17.3% of KushCo shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations for KushCo and Peak Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
KushCo01302.75
Peak Pharmaceuticals0000N/A

KushCo currently has a consensus target price of $1.8750, indicating a potential upside of 58.90%. Given KushCo's higher probable upside, research analysts clearly believe KushCo is more favorable than Peak Pharmaceuticals.

Profitability

This table compares KushCo and Peak Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
KushCo-65.89%-47.95%-31.39%
Peak PharmaceuticalsN/AN/AN/A

Valuation & Earnings

This table compares KushCo and Peak Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
KushCo$113.84 million1.65$-77,660,000.00($0.68)-1.74
Peak PharmaceuticalsN/AN/AN/AN/AN/A

Peak Pharmaceuticals has lower revenue, but higher earnings than KushCo.

Risk & Volatility

KushCo has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500. Comparatively, Peak Pharmaceuticals has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500.

Summary

KushCo beats Peak Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

Peak Pharmaceuticals (OTCMKTS:PKPH) and NSAV (OTCMKTS:NSAV) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Risk & Volatility

Peak Pharmaceuticals has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Comparatively, NSAV has a beta of 3.85, suggesting that its share price is 285% more volatile than the S&P 500.

Valuation and Earnings

This table compares Peak Pharmaceuticals and NSAV's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Peak PharmaceuticalsN/AN/AN/AN/AN/A
NSAVN/AN/AN/AN/AN/A

Profitability

This table compares Peak Pharmaceuticals and NSAV's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Peak PharmaceuticalsN/AN/AN/A
NSAVN/AN/AN/A

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Peak Pharmaceuticals and NSAV, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Peak Pharmaceuticals0000N/A
NSAV0000N/A

Summary

NSAV beats Peak Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

Peak Pharmaceuticals (OTCMKTS:PKPH) and Terra Tech (OTCMKTS:TRTC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.

Valuation & Earnings

This table compares Peak Pharmaceuticals and Terra Tech's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Peak PharmaceuticalsN/AN/AN/AN/AN/A
Terra Tech$28.05 million2.15$-46,930,000.00N/AN/A

Peak Pharmaceuticals has higher earnings, but lower revenue than Terra Tech.

Profitability

This table compares Peak Pharmaceuticals and Terra Tech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Peak PharmaceuticalsN/AN/AN/A
Terra Tech-261.88%-110.38%-62.41%

Analyst Ratings

This is a summary of current ratings and target prices for Peak Pharmaceuticals and Terra Tech, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Peak Pharmaceuticals0000N/A
Terra Tech0000N/A

Insider & Institutional Ownership

0.1% of Terra Tech shares are held by institutional investors. 6.7% of Terra Tech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Peak Pharmaceuticals has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500. Comparatively, Terra Tech has a beta of 2.4, suggesting that its stock price is 140% more volatile than the S&P 500.

Summary

Terra Tech beats Peak Pharmaceuticals on 4 of the 7 factors compared between the two stocks.


Peak Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Innovative Industrial Properties logo
IIPR
Innovative Industrial Properties
1.8$181.80-1.7%$4.42 billion$44.67 million58.84Analyst Revision
GrowGeneration logo
GRWG
GrowGeneration
1.5$45.16-4.3%$2.75 billion$79 million903.38Insider Selling
22nd Century Group logo
XXII
22nd Century Group
0.9$3.06-4.9%$489.20 millionN/A0.00Analyst Downgrade
Gap Down
KushCo logo
KSHB
KushCo
1.3$1.18-0.0%$187.47 million$113.84 million-1.97Gap Up
NSAV logo
NSAV
NSAV
0.3$0.02-1.1%$104.60 millionN/A0.00Gap Up
Terra Tech logo
TRTC
Terra Tech
0.7$0.26-3.7%$60.19 million$28.05 million0.00Decrease in Short Interest
Gap Up
General Cannabis logo
CANN
General Cannabis
0.6$0.68-4.4%$42.26 million$3.67 million0.00Gap Up
PVSP
Pervasip
0.4$0.01-0.0%$39.26 millionN/A0.00Increase in Short Interest
News Coverage
Gap Down
Grow Capital logo
GRWC
Grow Capital
0.6$1.09-8.3%$27.07 million$2.37 million0.00Gap Up
NMUS
Nemus Bioscience
0.6$0.12-0.0%$16.07 millionN/A0.00High Trading Volume
Leafbuyer Technologies logo
LBUY
Leafbuyer Technologies
0.5$0.16-6.5%$14.08 million$2.53 million0.00Gap Up
MassRoots logo
MSRT
MassRoots
0.6$0.02-1.8%$10.91 million$20,000.000.00
FutureWorld logo
FWDG
FutureWorld
0.5$0.00-0.0%$4.56 millionN/A0.00Gap Up
Mentor Capital logo
MNTR
Mentor Capital
0.5$0.17-5.9%$3.86 million$4.33 million-4.23Gap Down
NGBL
Notis Global
0.5$0.00-0.0%$3.00 millionN/A0.00
DigiPath logo
DIGP
DigiPath
0.5$0.04-6.1%$2.89 million$2.55 million-1.41Gap Down
CrowdGather logo
CRWG
CrowdGather
0.7$0.01-23.0%$1.60 million$160,000.000.00Increase in Short Interest
Gap Down
United Cannabis logo
CNAB
United Cannabis
0.4$0.01-0.0%$1.23 millionN/A0.00High Trading Volume
OPMZ
1PM Industries
0.4$0.00-0.0%$0.00N/A0.00Gap Down
AQSP
Acquired Sales
0.4$7.90-1.3%$0.00N/A0.00
AMMJ
American Cannabis
0.5$0.19-0.1%$0.00N/A0.00Gap Down
AmeriCann logo
ACAN
AmeriCann
0.4$1.30-0.8%$0.00N/A0.00Gap Up
Cannabics Pharmaceuticals logo
CNBX
Cannabics Pharmaceuticals
0.4$0.18-6.8%$0.00N/A0.00Gap Down
Cannabis Sativa logo
CBDS
Cannabis Sativa
0.5$0.72-1.4%$0.00N/A0.00
FRLF
Freedom Leaf
0.5$0.01-0.0%$0.00N/A0.00High Trading Volume
Gap Up
FUTL
FutureLand
0.4$0.00-0.0%$0.00N/A0.00
GB Sciences logo
GBLX
GB Sciences
0.5$0.05-7.7%$0.00N/A0.00Increase in Short Interest
Gap Down
GreenGro Technologies logo
GRNH
GreenGro Technologies
0.6$0.02-7.6%$0.00N/A0.00News Coverage
Gap Up
Harvest Health & Recreation logo
HRVSF
Harvest Health & Recreation
1.3$2.88-2.0%$0.00N/A0.00Gap Down
Marijuana Company of America logo
MCOA
Marijuana Company of America
0.5$0.01-0.0%$0.00N/A0.00Increase in Short Interest
Medical Marijuana logo
MJNA
Medical Marijuana
0.6$0.04-8.5%$0.00N/A0.00News Coverage
Gap Up
Medican Enterprises logo
MDCN
Medican Enterprises
0.5$0.00-12.5%$0.00N/A0.00Gap Up
MDCL
Medicine Man Technologies
0.5$2.39-13.0%$0.00N/A0.00High Trading Volume
Northsight Capital logo
NCAP
Northsight Capital
0.5$0.00-60.0%$0.00N/A0.00Gap Down
OWC Pharmaceutical Research logo
OWCP
OWC Pharmaceutical Research
0.6$0.01-2.1%$0.00N/A0.00Gap Down
Surna logo
SRNA
Surna
0.6$0.06-3.1%$0.00N/A0.00Gap Up
Ultrack Systems logo
MJLB
Ultrack Systems
0.6$0.09-3.2%$0.00N/A0.00Gap Up
BUDZ
WEED
0.6$0.52-0.0%$0.00N/A0.00Gap Down
Zoned Properties logo
ZDPY
Zoned Properties
0.6$0.59-2.6%$0.00N/A0.00Gap Down
ZZLL
ZZLL Information Technology
0.4$0.32-0.0%$0.00N/A0.00
This page was last updated on 4/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.